FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: FendX Technologies Inc. (the "Issuer").

Trading Symbol: FNDX

Number of Outstanding Listed Securities: 9,098,059 (as at March 31, 2026)

Date: April 6, 2026

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During the month of March, the Issuer continued its research and development activities on its nanotechnology products in development which included collaborating with McMaster University ("McMaster"). The Issuer is continuing its work on both its liquid surface coating (formerly referred to as the spray coating) where the Company has conducted

antimicrobial testing with a third party lab and has been preparing for pilot scale-up, as well as continuing its development collaboration with McMaster on the Company's Foley catheter coating.

2. Provide a general overview and discussion of the activities of management.

   During March, management focused on continuing oversight of its research and development activities being conducted at McMaster to advance its Foley catheter project and is preparing for pilot scale-up of its liquid surface coating. Management was successful in negotiating a signed amendment to the catheter collaborative research agreement with McMaster that governed the R&D activities on the catheter coating (the "CRA") extending the term to May 31, 2026 and reducing the Issuer's payments under this CRA. Given the promising performance of the liquid surface coating formulation, the Issuer made the decision to formally discontinue development of both REPELWRAP film and the original licensed bifunctional liquid coating formulation to focus on the new liquid surface coating, and the Issuer terminated both the License Agreement pursuant to a termination notice signed by the parties March 27, 2026, with an effective termination date of February 1, 2026, and the Nano-Coating License Agreement with McMaster pursuant to a termination notice signed by the parties March 27, 2026, with an effective termination date of February 2, 2026. These terminations eliminate future licensing payment obligations to McMaster.

   Management conducted third party lab testing on its liquid surface coating and has identified a potential third-party manufacturer capable of conducting a pilot scale-up run of the liquid surface coating. Management continues to focus on pursuing business development opportunities involving other technologies and/or products to complement the Issuer's current portfolio.

   Management attended to administrative matters, business development, and general management. Additionally, management negotiated proposed debt settlement agreements with three third party consultants aggregating $89,578 to be settled through the issuance of 242,102 shares, subject to CSE approval. Management also negotiated a renewal with Outside the Box Capital Inc. ("OTB") to extend the maturity date for their investor relations services. The Issuer holds regular management meetings regarding its business plan and executes action items that result from these meetings.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   N/A

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

The Issuer and McMaster signed a termination notice on March 27, 2026 to terminate the Standard License Agreement dated February 5, 2021 with McMaster with an effective termination date of February 1, 2026 which discontinued the license of the REPELWRAP film technology, and the Issuer ended further development of the REPELWRAP film and the Issuer and McMaster also signed a termination notice on March 27, 2026 to terminate the Liquid Surface (Spray) License Agreement dated effective May 23, 2023, with McMaster with an effective termination date of February 2, 2026, all to prioritize the development of the Issuer's new liquid surface coating formulation. Advancement of the new liquid coating resulted in the filing of a provisional patent announced on October 21, 2025.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   On March 30, 2025, the Issuer announced that the investor relations agreement between the Issuer and Outside the Box Capital Inc. (an arms-length party) previously announced March 12, 2025, July 7, 2025 and October 17, 2025 was renewed until June 30, 2026 at no additional cost to the Issuer but with a fee reduction of $28,080 inclusive of taxes.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   See item 2 and 4 for termination of the two license agreements with McMaster.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   As noted in items 2 and 4, the Issuer terminated both the Standard License Agreement and the Liquid Coating License Agreement, both with McMaster, a third party, which terminated the Issuer's licenses to certain technologies and intellectual property including several patent applications and issued patents related to both the REPELWRAP film technology and the original bifunctional spray technology.

8. Describe the acquisition of new customers or loss of customers.

   N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

   See item 7.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

    N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

    N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

    N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

    During March 2026, the Issuer entered into a loan agreement and received a loan of $45,000 from an associate of a Related Party. The loan is non-interest bearing and has no fixed term of repayment.

14. Provide details of any securities issued and options or warrants granted.

    N/A

15. Provide details of any loans to or by Related Persons.

    See item 13.

16. Provide details of any changes in directors, officers or committee members.

    N/A

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

    The recent emergence of global health threats, including the COVID-19 pandemic, a highly virulent variant of Mpox, interspecies transmission of avian influenza, and the rise of drug-resistant bacteria, highlights the importance of controlling the spread of pathogens. Many pathogens can spread via surfaces, posing potential public health risks. Global health authorities, like the CDC and WHO, are focused on developing strategies and recommendations to reduce pathogen transmission. The Issuer believes its surface protection products in development may contribute to the broader effort to mitigate pathogen transmission.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 6, 2026

Carolyn Myers
Name of Director or Senior Officer

"Carolyn Myers"
Signature
CEO and Director
Official Capacity

<table>
<tr><td>Issuer Details
Name of Issuer
FendX Technologies Inc.</td><td>For Month End March 31, 2026</td><td>Date of Report
YY/MM/DD
26/04/06</td></tr>
<tr><td colspan="3">Issuer Address
701 West Georgia Street, Suite 1500</td></tr>
<tr><td>City/Province/Postal Code
Vancouver, BC, V7Y 1C6</td><td>Issuer Fax No.
( )</td><td>Issuer Telephone No.
(800) 344-9868</td></tr>
<tr><td>Contact Name
Carolyn Myers</td><td>Contact Position
CEO</td><td>Contact Telephone No.
(800) 344-9868</td></tr>
<tr><td>Contact Email Address
carolyn@fendxtech.com</td><td colspan="2">Web Site Address
www.fendxtech.com</td></tr>
</table>